Covovax to get approval as booster in 10-15 days: SII CEO Adar Poonawalla
PTI
Pune, January 9Serum Institute of India’s Chief Executive Officer Adar Poonawalla has said their Covovax vaccine will get approval as a booster…
Browsing Tag
SII
Serum Institute to manufacture India’s 1st vaccine against cervical cancer after DGCI nod
Cervical cancer is the second most frequent cancer among women in India between the ages of 15 and 44.
Written by Harshit Sabarwal | Edited by Sohini Goswami, New Delhi
The Drugs Controller General of India (DCGI) on Tuesday approved…
DCGI grants marketing authorisation to SII’s qHPV vaccine against cervical cancer
PTI
New Delhi, July 12The Drugs Controller General of India (DCGI) on Tuesday granted market authorisation to Serum Institute of India (SII) to…
SII seeks nod to export 32.4 lakh doses of its Covid vaccine Covovax to US
The Serum Institute has sought the Centre’s approval to export 32.4 lakh doses of the COVID-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported to the country by any Indian manufacturer,…
Day after DCGI’s nod, SII seeks inclusion of Covovax in Covid immunisation prog
A day after India’s drug regulator approved Covovax for restricted emergency use in children aged 7 to 11 years, the vaccine maker Serum Institute has written to the Centre seeking its inclusion in the national COVID-19 vaccination…
DCGI panel to review on Friday SII applications for Covovax’s use among kids aged 2-7 yrs, 7-11 yrs
The subject expert committee on COVID-19 of India’s drug regulator will on Friday review the applications of Serum Institute of India seeking emergency use authorisation to use Covovax among those aged two to seven years and seven to 11…
SII’s Covovax vaccine now available for 12-17 age group at private centres
Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal,…
SII urges Centre to use free 100 mn Covishield doses by GAVI as cases rise
The Serum Institute of India has urged the Centre to use the available 10 crore doses of Covishield offered free of cost by GAVI under COVAX facility in view of rising…
SII urges Centre to use 10 cr Covishield doses offered free of cost by GAVI amid rising case
The Serum Institute of India has urged the Centre to use the available 10 crore doses of Covishield offered free of cost by GAVI under COVAX facility in view of rising COVID-19 cases in the country, an official source said.
The Pune-based…